147
Participants
Start Date
December 22, 2021
Primary Completion Date
August 19, 2022
Study Completion Date
August 19, 2022
Centanafadine
Sustained-release oral tablets
Placebo
Oral tablets
Manhattan Behavioral Medicine, New York
Medical Research Network, LLC, New York
Richmond Behavioral Associates, Staten Island
iResearch Atlanta, Decatur
Psych Atlanta, PC, Marietta
Clinical Neuroscience Solutions - Jacksonville, Jacksonville
Miami Dade Medical Research Institute, Miami
Clinical Neuroscience Solutions, Inc., Memphis
Craig and Frances Linder Center of Hope, Mason
Midwest Clinical Research Center, Dayton
St. Charles Psychiatric Associates & Midwest Research Group, Weldon Spring
Collective Medical Research, Prairie Village
Psychiatric Associates, Overland Park
FutureSearch Trials - Dallas, Dallas
Psychiatry + Psychotherapy Partners Austin, Austin
Mountain View Clinical Research, LLC, Denver
NoesisPharma, LLC, Phoenix
Southern California Research LLC, Beverly Hills
Pharmacology Research Institute - San Fernando Valley, Encino
Pacific Clinical Research Management Group LLC, Upland
Collaborative Neuroscience Research, LLC, Garden Grove
Boston Clinical Trials, Boston
ActivMed Practices and Research - Portsmouth, Portsmouth
Center for Emotional Fitness, Cherry Hill
Princeton Medical Institute, Princeton
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY